Axel Baumgarten - Concepedia

Author

Axel Baumgarten

Center for HIV and Hepatogastroenterology

Also Known As

A BAUMGARTEN, A Baumgarten, A. Baumgarten, Axel Baumgarten, Axel Baumgarten (778024), Baumgarten, Axel, Eva Wolf, Jörg Claus, Marc-Antoine Valantin, Petra Panstruga

153

Publications

Citations

H-Index

Concepts

All Affiliations

Center for HIV and Hepatogastroenterology Infektionsmedizinisches Centrum Hamburg University Hospital Bonn University of Bonn Klinikum Leverkusen

About

Axel Baumgarten is an author at Center for HIV and Hepatogastroenterology specializing in medicine, hiv, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.1K
2	Public Health	5	5	262
3	Epidemiology	5	5	273
4	Health Sciences	1	1	23
5	Cell Biology	1	1	111

Axel Baumgarten

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond, New England Journal of Medicine	2020	523
Brief Report Sharon Walmsley, Axel Baumgarten, Juan Berenguer, JAIDS Journal of Acquired Immune Deficiency Syndromes Noninferiority StudyImmunodeficienciesSingle StudyPharmacologyClinical Trials	2015	215
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe Patrick Ingiliz, Thomas Martin, Alison Rodger, Journal of Hepatology Sexual HealthViral PersistenceSpontaneous Clearance RatesViral HepatitisWestern Europe	2016	173
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, The Lancet HIV Week 96Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirology	2019	160
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, The Lancet HIV Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyNon-inferiority Trial	2018	140
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials Giuliano Rizzardini, Edgar T. Overton, Chloe Orkin, JAIDS Journal of Acquired Immune Deficiency Syndromes	2020	137
The ubiquitin ligase APCCdh1 is required to maintain genome integrity in primary human cells Dirk Engelbert, Dominik Schnerch, Axel Baumgarten, Oncogene Genome InstabilityUbiquitin Ligase Apccdh1GeneticsPrimary Human CellsGenomic Mechanism	2007	111
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, The Lancet HIV Treatment And PreventionAntiretroviral-naive AdultsClinical TrialsAntiviral Drug DevelopmentAntiviral Therapy	2019	92
Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV–Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01) Patrick Ingiliz, Stefan Christensen, Torben Kimhofer, Clinical Infectious Diseases	2016	72
Pegylated Interferon-α for the Treatment of Sexually Transmitted Acute Hepatitis C in HIV-Infected Individuals Martin Vogel, Jacob Nattermann, Axel Baumgarten, Antiviral Therapy	2006	71

Page 1